What is AMRX's P/E ratio?

AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK (AMRX) currently trades at a P/E ratio of 48.28.

AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK reports a Return on Equity (ROE) of -269.45%.

What is AMRX's dividend yield?

AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK offers a dividend yield of 0.00%.

What is AMRX's Quality Score?

Our AI rates AMRX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy AMRX?

Our AI Timing Score for AMRX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does AMRX belong to?

AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

AMRX (NASDAQ) Stock Analysis | AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

AMRX AI Analysis Summary

Our AI summary for AMRX: AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 48.28, ROE of -269.45%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

AMRX

AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK

USD 18.32

-0.18 (-0.97%) Day Change

Watchlist Portfolio Compare Chart

48.28

P/E

-56.97

D/E

-269.5%

ROE

3.5%

ROA

0.00%

Div Yield

-0.65

PEG

AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 18.32 Price -0.18 (-0.97%) Day Change	NEWS SCORE: 96

AMRX, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

50%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	96
Magic Formula Rank by ROA	2783
Magic Formula Rank by ROE	2783
Magic Formula Rank by ROIC	1824
Price	18.32
PBV / Sector	-128.51 / 3.22
Earning Per Share	0.38

PE / Sector	48.28 / 29.79
PEG or PE/Growth / Sector	-0.65 / 0.13
Average 1M Daily Value	31.82 M GREAT
Average 1W Daily Value	33.89 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	4.02 / 15.21
NPM Average (%) / Sector	-1.43 / -10.83
NPM Change Average (%) / Sector	-27.45 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	3.46 / 8.15
ROA Average (%) / Sector	-0.75 / 2.87
ROA Change Average (%) / Sector	-18.39 / 112.70
ROE (%) / Sector	-269.45 / -1.02
ROE Average (%) / Sector	-146.49 / 8.35
ROE Change Average (%) / Sector	179.80 / 385.91 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 07:59:28
Symbol	AMRX
Name	AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	319.33 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	5,907.63 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807

Phone: 908 947 3120

Website: https://www.amneal.com

Employees: 8,700

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.